World Czechs May Use Russian Jabs Without European Regulator Approval
Biden's polling is steadier than Trump's
Poll of the week: A Quinnipiac University poll finds that President Joe Biden's job approval rating stands at 52% to a disapproval rating of 38% among registered voters. © Provided by CNN Biden's average approval rating is 55% and his average disapproval rating is 39%, which makes for an average net approval rating of +16 points. What's the point: Nothing ever seemed to shake Donald Trump's job approval rating. It moved less than any other president in the polling era. So far, Biden's proven to be even steadier than Trump. And very much unlike Trump, people seem to actually like what Biden is doing.
The Czech Republic won’t wait for the European Union regulator’s approval to use a Russian coronavirus vaccine, Prime Minister Andrej Babis said.
The country has taken “concrete steps” to purchase the Sputnik V vaccine and will use it if Czech health authorities approve, Babis said on Sunday in a weekly debate show on Prima TV. Local drug authorities’ assessment of the safety of the vaccine “would be sufficient” to use the shots, he said.
“It also depends on whether we will be able to purchase them as there’s already a huge demand from other states,” the prime minister said.
Countries across the EU are struggling with vaccine supply shortages. The Czech Republic, which is fighting an acute pandemic outbreak, will be imposing its strictest lockdown yet beginning on Monday to prevent a collapse of its health-care system.
For more articles like this, please visit us at
©2021 Bloomberg L.P.
EMA to Start Review Process for Russia’s Sputnik V Covid Vaccine .
The European Medicines Agency said it has started a rolling review of Russia’s Sputnik V Covid-19 vaccine to test compliance with safety and quality standards, the first major step in gaining approval for use in the European Union. “The rolling review will continue until enough evidence is available for formal marketing authorization application,” the agency said in a statement Thursday. “While EMA cannot predict the overall timelines, it should take less time than normal to evaluate an eventual application because of the work done during the rolling review.